Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells by Lisek, Kamil et al.
Oncotarget20508www.oncotarget.com
Mutant p53 tunes the NRF2-dependent antioxidant response to 
support survival of cancer cells
Kamil Lisek1,4, Elena Campaner1,2, Yari Ciani1, Dawid Walerych1,3 and Giannino Del 
Sal1,2
1National Laboratory CIB, Area Science Park Padriciano, Trieste 34149, Italy
2Department of Life Sciences, University of Trieste, Trieste 34127, Italy
3Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw 02-106, Poland
4Present address: Max-Delbrück-Centrum for Molecular Medicine, Berlin 13092, Germany
Correspondence to: Giannino Del Sal, email: gdelsal@units.it
Dawid Walerych, email: dwalerych@imdik.pan.pl
Keywords: NRF2; mutant p53; cancer; oxidative stress
Received: August 20, 2017    Accepted: March 09, 2018    Published: April 17, 2018
Copyright: Lisek et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source 
are credited.
ABSTRACT
NRF2 (NFE2L2) is one of the main regulators of the antioxidant response of the 
cell. Here we show that in cancer cells NRF2 targets are selectively upregulated or 
repressed through a mutant p53-dependent mechanism. Mechanistically, mutant p53 
interacts with NRF2, increases its nuclear presence and resides with NRF2 on selected 
ARE containing gene promoters activating the transcription of a specific set of genes 
while leading to the transcriptional repression of others. We show that thioredoxin 
(TXN) is a mutant p53-activated NRF2 target with pro-survival and pro-migratory 
functions in breast cancer cells under oxidative stress, while heme oxygenase 
1 (HMOX1) is a mutant p53-repressed target displaying opposite effects. A gene 
signature of NRF2 targets activated by mutant p53 shows a significant association 
with bad overall prognosis and with mutant p53 status in breast cancer patients. 
Concomitant inhibition of thioredoxin system with Auranofin and of mutant p53 with 
APR-246 synergizes in killing cancer cells expressing p53 gain-of-function mutants.
INTRODUCTION
The transcription factor nuclear factor erythroid 
2-related factor 2 (NRF2) is the main and evolutionary 
conserved regulator of the antioxidant pathways in the 
cell. In response to oxidative stress, the inhibitor Keap1 
cannot degrade NRF2, and newly synthesized NRF2 
accumulates, translocates to the nucleus and drives the 
transcription of ARE containing genes [1]. The role of the 
NRF2-Keap1 pathway in cancer initiation, progression and 
chemoresistance has been studied extensively in the recent 
years. Keap1 mutations activating NRF2 or mutations in 
NRF2 gene itself are frequent events in many cancer types 
[2, 3]. Moreover, various oncogenes have been reported 
to impact the NRF2 pathway by upregulating total mRNA 
and protein levels of NRF2 [4, 5]. NRF2 controls key 
components of endogenous antioxidant systems in both 
cancer and normal cells [1, 6]. Until now over 500 genes 
have been reported to be under NRF2 control [7]. While 
in normal cells the NRF2/Keap1 antioxidant pathway 
plays a crucial role in maintaining cellular homeostasis 
and preventing tumorigenesis [1], in cancer cells high 
expression of NRF2-regulated genes provides them with 
cytoprotection, contributing to their oncogenic capabilities 
[8, 9].
Mounting evidence links the oncogenic activities 
of mutant p53 [10] to different aspects of NRF2 
transcriptional activity [11] although reported results 
open a number of questions on the interplay between 
these two factors, as mutant p53 was shown to repress 
the elements of the NRF2-dependent oxidative stress 
response [12], while other researchers showed that 
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mutant p53 activates NRF2 gene transcription [13]. We 
have previously demonstrated that while in cancer cells 
mutant p53 activates proteasome genes in cooperation 
with NRF2, it indeed simultaneously represses another 
NRF2 target gene - heme oxygenase 1 (HMOX1) [14]. The 
physiological significance of this mutant p53-dependent 
bi-directional NRF2 target regulation in cancer cells has 
remained unclear.
Here, we investigate how mutant p53 impacts on 
NRF2 activity acting as a molecular switch that turns on- 
or off- specific components of the NRF2 transcriptional 
program thus tuning NRF2 activity in cancer cells. We also 
provide evidence that simultaneous targeting of mutant 
p53 and of the thioredoxin system by combining APR-
246/PRIMA-1MET and Auranofin, synergizes providing 
a therapeutic advantage against breast cancer cells.
RESULTS
Mutant p53 differentially regulates NRF2 
transcriptional targets
In order to evaluate the impact of mutant p53 on 
the expression of NRF2 transcriptional program, we 
perused already available datasets to sort out a signature 
consisting of well established NRF2 target genes which 
represent various biological processes important for 
normal and cancer cell metabolism. We selected key NRF2 
downstream targets regulating the antioxidant systems of 
the cell, such as glutathione (GCLC, GCLM), thioredoxin 
(TXN, TXNRD1), as well as genes encoding for: cystine 
antiporter (SLC7A11), quinone oxidoreductase (NQO1), 
heme oxygenase 1 (HMOX1), multidrug resistance 
proteins (ABCC3, ABCC5), proteasome subunits (PSMA2, 
PSMC1, PSMD10) and phosphoserine aminotransferase 
(PSAT1) [7, 15–17].
In order to understand to what extent the NRF2 
transcriptional profile differs between normal and cancer 
cells of the breast epithelium, we compared MDA-
MB-231 (a breast cancer cell line bearing missense mutant 
p53), MCF7 (a breast cancer cell line harboring wild-type 
p53) and MCF10A (untransformed, immortalized breast 
epithelial cells) for basal expression of the NRF2 gene 
signature (Figure 1A). Breast cancer cells (MDA-MB-231 
and MCF7) showed a markedly higher expression of 
NRF2 and of all investigated NRF2 targets than normal 
cells (MCF10A), confirming previous observations from 
other cellular models [5, 18, 19].
We expected from our previous study that mutant 
p53 may differentially affect subsets of NRF2 targets [14]. 
Hence, we compared the expression of selected NRF2 target 
genes between normal breast epithelial MCF10A cells 
bearing wild-type p53 (wtp53), MCF10A cells silenced 
for TP53 (MCF10A+shTP53) and MCF10A cells silenced for 
wild-type TP53, ectopically overexpressing the oncogenic 
mutant p53 (mtp53) R280K (MCF10A+mtp53 R280K). In 
this experimental setup we observed that in the presence 
of mutant p53 only a subset of the NRF2 transcriptional 
program is upregulated, while other NRF2 targets are 
repressed. MCF10A+mtp53 R280K expressed higher levels of a 
proteasome subunit gene (PSMC1), of thioredoxin system 
genes (TXN, TXNRD1), and of glutathione (GCLM) in 
comparison to normal MCF10A cells, while the expression 
of targets such as HMOX1, SLC7A11, ABCC3 was repressed 
in the presence of the mutant p53 gain of function (GOF) 
variant (Figure 1B).
Interestingly, in MCF10A cells stably expressing the 
oncogenic variant of HRAS (MCF10A+HRAS), expression 
of all investigated NRF2 targets was significantly 
upregulated, confirming previous reports in different 
cellular systems indicating that other oncogenes (i.e. 
oncogenic alleles of KRAS, HRAS, BRAF or CMYC) have 
an overall activating effect on the NRF2 transcriptional 
activity [5] (Figure 1B).
We confirmed the differential regulation of NRF2 
transcriptional targets by mutant p53 also in MDA-
MB-231 breast cancer cells in which we silenced mutant 
TP53 expression with siRNAs [14, 20]. In this context, 
we observed a downregulation of PSMC1, TXN, TXNRD1, 
and GCLM, and an upregulation of HMOX1, SLC7A11 
and ABCC3 transcription (Figure 1C and Supplementary 
Figure 1A). Similarly, in p53-null H1299 lung cancer cells 
upon stable introduction of mutant p53 variant R175H, 
we observed an upregulation of TXN and TXNRD1 and 
a concomitant downregulation of HMOX1 and ABCC3 
transcription (Supplementary Figure 1B). Silencing of 
NRF2 abolished mutant p53 ability to sustain TXN and 
TXNRD1 mRNA levels indicating that mutant p53 requires 
NRF2 to promote the transcription of these genes.
Since NRF2 plays a major role as an antioxidant 
response regulator in cancer and in normal cells we sought 
to test if the regulation of the expression of NRF2 targets 
by mutant p53 is maintained also under the oxidative 
stress conditions. We first tested different oxidative 
stress inducers in promoting NRF2 activation in MDA-
MB-231 cells by analyzing both NRF2 localization 
and the expression levels of its targets. As shown in 
Supplementary Figure 2A, 2B, H2O2, menadione and 
sodium arsenite induced NRF2 nuclear localization and 
transcription of its targets in a similar manner. Considering 
the reported toxic effect of menadione and sodium arsenite 
[21–24], we selected H2O2 as oxidative stress inducer 
for the next experiments. We then treated MCF10A+ 
RAS, MCF10A+mtp53 R280K or MDA-MB-231 cells with 
H2O2 and observed that NRF2 targets and NRF2 itself 
are transcriptionally activated in response to exogenous 
oxidative stress stimuli and that mutant p53 regulates 
NRF2 targets in a similar way as in unstressed conditions 
(Figure 1D and Supplementary Figure 2C, 2D). Abrogating 
the expression of NRF2 with siRNA inhibits NRF2 target 
expression in both normal and oxidative stress conditions 
(Figure 1C, 1D and Supplementary Figure 2C, 2D).
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Next, we validated the effect of mutant p53 on NRF2 
transcriptional program performing rescue experiments in 
MDA-MB-231 cells in which we stably silenced mutant 
TP53 (MDA-MB-231+shTP53). We investigated TXN as a 
representative of NRF2 targets activated by mutant p53, 
and HMOX1 among NRF2 targets repressed by mutant p53. 
In this setup, we observed downregulation (at both mRNA 
and protein levels) of TXN, and upregulation of the mRNA 
level of HMOX1 (Figure 1E and Supplementary Figure 2E). 
Reintroducing HA-tagged mutant p53 in these cells (MDA-
Figure 1: Mutant p53 differentially regulates the expression of NRF2 transcriptional targets. (A) Expression of selected 
NRF2 targets in breast cancer cell line MDA-MB-231 (bearing mutant p53 R280K), breast cancer cell line MCF7 (bearing wt p53) in 
comparison with normal epithelial breast cell line MCF10A (bearing wt p53). (B) Expression of NRF2 targets in MCF10A cells. Normal 
epithelial cells (MCF10A) stably transfected with empty retroviral vector (Ctrl), vector encoding oncogenic variant H-Ras G12V (HRAS), 
vector encoding shRNA targeting TP53 transcript (shTP53), and mutant p53 CDS shRNA-resistant HA-tagged variant R280K, stably 
introduced into the MCF10A shTP53 cell line (+mtp53 R280K). (C,D) Effect of mutant TP53 or NRF2 silencing on the selected NRF2 
targets in MDA-MB-231 cells in unstressed conditions (C) or under oxidative stress induced by incubation of MDA-MB-231 cells with 
500μM H2O2 for 12 hours (D). (E) Expression levels of HMOX1 and TXN in MDA-MB-231 cells stably silenced for control (shCtrl), TP53 
(shTP53), or TP53 together with stable mutant p53 R280K overexpression (shTP53 + HA R280K). Data shown in A-E are the means ± 
s.d. of n=3 independent experiments, ANOVA test with Bonferroni correction: * p<0.05, ** p<0.01, *** p<0.001. Expression levels are given 
relative to ACTB.
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Figure 2: Mutant p53-NRF2 interaction is crucial for regulating NRF2 targets. (A) Western blot analysis of co-
immunoprecipitation (coIP) of NRF2 with p53R175H and with p53 peptide aptamers (p53 PA’s) in lysates from H1299 cells upon transient 
transfection with empty- (HA), p53R175H- (FL) or p53 PA vectors. NRF2-antibody immunoprecipitated proteins (IP) and input cell lysates 
(INPUT) were analyzed by western blot with the indicated antibodies; size markers are indicated. (B) Western blot analysis of the interaction 
of NRF2 with mutant p53 and p53 PA’s in co-IP assay upon overexpression of empty- (HA) or TNV p53 PA’s vectors in H1299 cells stably 
overexpressing p53R175H. Upon IP with the anti-NRF2 antibody, immunoprecipitated proteins (IP) and input cell lysates (INPUT) were 
analyzed by western blot with the indicated antibodies; size markers are indicated. (C) Western blot analysis of the interaction of NRF2 
with mutant p53 in co-IP assay upon overexpression of empty- (0) or increasing amounts of pep1-encoding vector (15μg, 30μg, 60μg) into 
H1299 cells stably overexpressing p53R175H. Upon IP with anti-NRF2 antibody, immunoprecipitated proteins (IP) and input cell lysates 
(INPUT) were analyzed by western blot with the indicated antibodies; size markers are indicated. (D) Expression of selected NRF2 targets 
in H1299 cells transfected with empty- or p53 R175H vector (R175H) alone or in combination with mutant p53 silencing (siTP53) or 
with pep1 overexpression. Expression levels are given relative to ACTB. (E,F) Chromatin immunoprecipitation (ChIP) of NRF2-binding 
regions from HMOX1 (E) and TXN (F) transcription regulatory sequences using anti-p53 or anti-NRF2 antibodies upon siRNA-mediated 
silencing of mutant TP53, NRF2 or control siRNA (siCtrl). ChIP enrichment in anti-p53 (DO-1) and anti-NRF2 antibody IP is compared 
to the control IgG antibody IP. Data shown in D-F are the means ± s.d. of n=3 independent experiments, ANOVA test with Bonferroni 
correction: * p<0.05, ** p<0.01, *** p<0.001.
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MB-231+shp53/+HA R280K) we observed a rescue of TXN gene 
expression and of the corresponding thioredoxin (Trx) protein 
level, coupled with the transcriptional repression of HMOX1 
(Figure 1E and Supplementary Figure 2E). Heme oxygenase 
1 (HO-1) protein levels were undetectable by western blot 
analysis in unstressed conditions (data not shown).
We next evaluated whether the effect of mutant p53 
on NRF2 targets involved a modulation of NRF2 protein 
Figure 3: Cancer cell viability and migration under oxidative stress rely on the mutant p53-depedent differential 
regulation of NRF2 targets. (A) Viability measurement of MDA-MB-231 cells upon TP53, NRF2, TXN, HMOX1 or control silencing. 
(B) Viability measurement of MDA-MB-231 cells stably silenced for control (shCtrl), TP53 (shTP53), or TP53 together with stable mutant 
p53 R280K overexpression (shTP53 + R280K) in unstressed (NT) or under oxidative stress conditions (100μM or 500μM H2O2, 48 hours 
treatment). (C) Viability measurement of MDA-MB-231 cells upon TP53, NRF2, TXN, HMOX1 or control silencing under low oxidative 
stress conditions induced by overnight treatment with 100μM H2O2. (D) Viability measurement of MDA-MB-231 cells upon co-silencing 
of p53 and NRF2 downstream targets (HMOX1 or TXN). (E) Viability measurement of MDA-MB-231 cells after co-silencing of p53 and 
NRF2 downstream targets (HMOX1 or TXN) under low oxidative stress conditions induced by overnight treatment with 100μM H2O2. (F) 
Transwell migration assays of MDA-MB-231 cells upon TP53, NRF2, TXN, HMOX1 or control silencing. (G) Transwell migration assays 
of MDA-MB-231 cells upon TP53, NRF2, TXN, HMOX1 or control silencing under low oxidative stress conditions induced by overnight 
treatment with 100μM H2O2. Data shown in A-G are the means ± s.d. of n=3 independent experiments, ANOVA test with Bonferroni 
correction: * p<0.05, ** p<0.01, *** p<0.001.
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levels. We performed both ectopic expression of two 
TP53 mutants in MCF10A and silencing of mutant TP53 
in different cell lines (MDA-MB-231, MDA-MB-468, 
BT549 and SUM149) and analyzed NRF2 levels. As 
shown in Supplementary Figure 3A-3C modulation of 
mutant p53 did not have a strong impact on NRF2 protein 
levels. Taken together these results indicate that mutant 
p53 exerts both positive and negative control over NRF2 
transcriptional activity without altering the NRF2 protein 
levels.
Mutant p53-NRF2 interaction is crucial for 
regulating NRF2 targets in mutant p53 bearing 
cancer cells
We have previously shown that mutant p53, via 
its DNA-binding domain, interacts with NRF2 and 
cooperatively both proteins activate proteasome subunit 
genes’ transcription [14]. We have also hypothesized that 
the interaction between mutant p53 and NRF2 is crucial 
for the transcriptional regulation of proteasome subunit 
genes and possibly, of other NRF2 targets but we did 
not characterize in detail the region of p53 involved in 
NRF2 binding. To this aim we used here a previously 
described protein scaffold system to expose peptide 
aptamers in cells for protein interaction studies [25]. 
Six peptides of the length of 30 amino acids containing 
sequences corresponding to the human p53 DNA-binding 
domain (DBD) were expressed inside the scaffold 
protein fused with HA tag cloned within an eukaryotic 
expression vector [25] (Supplementary Figure 3D). 
The p53-null H1299 cancer cells were transfected with 
plasmids expressing the full-length mutant p53 R175H 
or the six peptides spanning the DBD of mutant p53 and 
cell lysates were subjected to immunoprecipitation of 
endogenous NRF2. As shown in Figure 2A among the six 
peptides only peptide1 (pep1) corresponding to aa 98-128 
of the mutant p53 DBD was co-immunoprecipitated with 
NRF2. Moreover, in H1299 cells stably overexpressing 
full-length mutant p53, ectopic expression of the plasmid 
vector carrying pep1 was able to compete with mutant 
p53 full-length protein for binding to endogenous NRF2, 
as shown by co-immunoprecipitation assays with the 
anti-NRF2 antibody (Figure 2B). This effect increased 
when increasing amount of the pep1 encoding vector was 
used (Figure 2C).
We next verified whether this peptide was able 
to interfere with the mutant p53-dependent regulation 
of NRF2 transcriptional targets. As shown before [14], 
introduction of mutant p53 variant R175H in the p53-null 
background of H1299 cells caused the up-regulation of 
proteasome subunit genes (PSMA2 and PSMC1) known 
targets of NRF2, and this effect was strongly counteracted 
by overexpressing pep1 (Supplementary Figure 3E).
Next, we asked if pep1 by preventing mutant p53/
NRF2 interaction could affect also other NRF2 targets 
differentially regulated by mutant p53. In H1299 cells 
both transient and stable overexpression of mutant p53 
R175H enhanced TXN and PSMC1 gene transcription, 
while significantly repressed HMOX1 expression (Figure 
2D). Conversely, upon downregulation of mutant p53 
levels with a specific siRNA, H1299+mtp53R175H cells showed 
a significant up-regulation of HMOX1 transcript and a 
down-modulation of TXN and PSMC1 gene transcription. 
We also observed comparable, opposite effects on TXN 
and PSMC1 and on HMOX1 in mutant TP53-silenced 
H1299+mtp53R175H cells and in H1299+mtp53R175H cells 
overexpressing pep1 (Figure 2D).
These results indicate that aa 98-128 of p53 are 
involved in the interaction of mutant p53 with NRF2 and 
that expression of a peptide corresponding to that sequence 
is able to dissociate the complex between the two proteins 
with a clear impact on the transcriptional regulation of 
NRF2 targets by mutant p53.
Mutant p53 presence on ARE elements in 
regulatory regions of NRF2 targets is required 
for activation of their transcription
To dissect the mechanism by which the concerted 
action of mutant p53 and NRF2 can either enhance or 
repress transcription, chromatin immunoprecipitation 
(ChIP) experiments were performed in MDA-MB-231 
cells using NRF2 or p53 antibodies and the regulatory 
regions of both activated and repressed NRF2 target genes 
were analyzed.
We found out that in MDA-MB-231 cells NRF2 
binds the regulatory elements of its targets even without 
externally applied oxidative stress (Figure 2E, 2F and 
Supplementary Figure 3F, 3G).
In these conditions mutant p53 is co-recruited on 
TXN and TXNRD1 gene promoters together with NRF2 
(Figure 2F and Supplementary Figure 3G). Silencing 
of mutant TP53 decreased NRF2 recruitment to these 
regions, while silencing of NRF2 completely abolished 
mutant p53 binding indicating that mutant p53 requires 
NRF2 for binding ARE sequences on activated gene 
promoters, an effect that we have previously shown also 
for proteasome subunit genes [14]. On the other hand 
we did not find mutant p53 binding to the promoter of 
ABCC3, nor to an ARE-containing distant enhancer (EN2) 
of HMOX1, which is a canonical regulatory element 
bound and activated by NRF2 [26] (Supplementary Figure 
3F and Figure 2E). Silencing of mutant TP53 increased 
the efficiency of NRF2 binding to the HMOX1 enhancer 
(Figure 2E).
In normal cells under unstressed conditions NRF2 
resides mainly within the cytoplasm, while in cancer 
cells, the intracellular chronic oxidative stress causes the 
accumulation of a fraction of NRF2 in the nucleus in the 
absence of external stress stimuli [14, 27]. Interestingly, 
we observed that overexpression of two different GOF 
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mutant p53 variants in H1299 induced an increase in 
nuclear NRF2 (Supplementary Figure 4A, 4B) which 
was comparable to that observed upon oxidative stress 
induction (Supplementary Figures 2A and 4C). Moreover, 
when we silenced mutant TP53 expression in MDA-
MB-231 or in MCF10A overexpressing mutant p53 
R175H, we observed that the majority of NRF2 was 
localized in the cytoplasm (Supplementary Figure 4D, 4E).
These results suggest that mutant p53 increases 
NRF2 localization to the nucleus of cancer cells where 
Figure 4: NRF2 transcriptional program activated by mutant p53 is associated with poor overall prognosis and with 
the mutant status of p53 in breast cancer patients. (A) (upper panels) Left, association of the mutant p53 activated signature with 
a survival of breast cancer patients. The red curve (“high”) represents the survival of patients with high expression of mutant p53 activated 
signature, black curve (“low”) – low expression of mutant p53 activated signature. HR – hazard ratio; log-rank P – log-rank test p-value for 
the curves comparison. Right, association of the mutant/wt TP53 status and expression of NRF2 targets activated by mutant p53 listed in the 
table (TXN, TXNRD1, GCLM, PSMC1). Box plot: diff – difference in mean gene expression in mutant vs. wt p53 status samples; p-value is 
derived from Mann–Whitney U test. Centre represents the median, box extremes indicate the first and third quartiles, and whiskers extend 
to the extreme values included in the interval calculated as ±1.58 IQR/sqrt(n), where the IQR (interquartile range) is calculated as the third 
quartile minus the first values included in the interval calculated as ±1.58 IQR/sqrt(n), where the IQR (interquartile range) is calculated 
as the third quartile minus the first quartile. (lower panel) List of genes included in the signature. (B) (upper panels) Left, association of 
the mutant p53 repressed signature with survival of breast cancer patients. The red curve (“high”) represents the survival of patients with 
high expression of mutant p53 repressed signature, black curve (“low”) – low expression of mutant p53 repressed signature. HR – hazard 
ratio; log-rank P – log-rank test p-value for the curves comparison. Right, association of the mutant/wt TP53 status and expression of NRF2 
targets repressed by mutant p53 (HMOX1, x-CT, ABCC3). Box plots: as in (A), diff – difference in mean gene expression in mutant vs wt 
p53 status samples; p-value is derived from Mann–Whitney U test). (lower panel) List of genes included in the signature.
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it redirects NRF2 to ARE elements of specific genes, 
activating their transcription (TXN, TXNRD1), and 
conversely it sequesters NRF2 from other targets 
(HMOX1, ABCC3) leading to their downregulation.
Cancer cell survival and migration under 
oxidative stress relies on the mutant p53-
depedent differential regulation of NRF2 targets
H2O2 is a widely used inductor of oxidative stress 
that activates NRF2-dependent response mechanism [28–
30] and mimics the characteristic chronic oxidative stress 
environment of tumor cells [31–33]. As reported by 
others, via H2O2 production, oxidative stress modulates 
tumor growth and spread [31, 34] and sub-cytotoxic 
levels of H2O2 in tumors differentially modulate the 
behavior of normal and neoplastic cells [35]. In order 
to address the impact of the NRF2 targets activated or 
repressed by mutant p53 on mutant p53-dependent cancer 
cells phenotype, we performed viability experiments in 
cancer cells either exposed or not to exogenous oxidative 
stress by H2O2 (Figure 3A–3E and Supplementary 
Figure 4F).
In normal conditions, in the absence of H2O2, 
silencing of either mutant TP53 or NRF2 significantly 
decreased MDA-MB-231 cell viability. Similar effects 
were observed upon silencing of TXN gene, an NRF2 
target induced by mutant p53 (Figure 3A). In contrast, 
silencing of HMOX1, an NRF2 target repressed by 
mutant p53, had no effect on the viability of MDA-
MB-231 cells (Figure 3A). Treatment of MDA-MB-231 
breast cancer cells with 100μM H2O2 (low oxidative 
stress) induced a 30% decrease of cell viability, while 
upon 500μM treatment (high oxidative stress) cell 
viability was reduced by 70% (Supplementary Figure 
4F). As expected both low and high oxidative stress 
activated NRF2 and its targets, albeit to a different 
extent (Supplementary Figure 2A, 2B). Silencing of 
mutant TP53 further sensitized cells to low and high 
oxidative stress, but overexpression of mutant p53 
in MDA-MB-231 cells, silenced for the endogenous 
mutant TP53 variant R280K, rescued cell survival 
conferring a cytoprotective effect to cancer cells (Figure 
3B). In low oxidative stress conditions, silencing of 
TXN expression further reduced cell viability, while 
silencing of HMOX1 had a pro-survival effect (Figure 
3C). Moreover, we observed that combining HMOX1 
and mutant TP53 silencing counteracted the impact 
of the sole mutant p53 silencing on cell viability in 
both normal and induced oxidative stress conditions, 
while silencing of both mutant TP53 and TXN further 
decreased the cell viability (Figure 3D, 3E). Under 
the high oxidative stress (treatment with 500μM 
H2O2), cancer cell viability was reduced by 90% upon 
silencing of either HMOX1 or TXN (Supplementary 
Figure 4G, 4H), indicating that both antioxidant defense 
mechanisms have to be intact for cancer cell survival in 
high oxidative stress conditions.
We next wanted to evaluate the impact of TXN and 
HMOX1 silencing also on the migration capabilities of 
MDA-MB-231 in both unstressed and oxidative stress 
conditions. As shown in Figure 3F, 3G silencing of 
HMOX1 resulted in increased migration of MDA-MB-231 
cells under low oxidative stress. In contrast, silencing of 
TXN resulted in a drop of the migration rate both upon 
exposure to low oxidative stress and under normal 
conditions.
Altogether these results suggest that in the low 
oxidative stress conditions, cancer cell survival and 
migration depends on selective induction of a specific 
oxidative stress response, namely the thioredoxin system, 
while keeping at low levels other antioxidant systems, 
such as the heme oxygenase 1 system. Our data also 
indicate the mutant p53/NRF2 axis as a key player in fine-
tuning of this response.
Expression of NRF2 transcriptional targets 
activated by mutant p53 is associated with poor 
prognosis and with the mutant status of p53 in 
breast cancer patients
Our data indicates a dual role of mutant p53 in 
regulating NRF2 transcriptional targets in vitro. To 
understand the relevance of this mechanism in vivo, 
we investigated the association of the expression levels 
of NRF2 targets that we found differentially regulated 
by mutant p53 in vitro with the mutant p53 status in a 
cohort of breast cancer patients (Figure 4). Expression 
of genes upregulated by mutant p53 (signature 1, Figure 
4A) associated with the mutant status of p53 in breast 
cancer patients according to the TCGA dataset. Moreover, 
high expression of these genes showed association with 
poor prognosis in breast cancer (Figure 4A), in contrast 
with the expression of genes downregulated by mutant 
p53 (signature 2, Figure 4B). Moreover, expression 
of signature 2 or of NRF2 did not correlate with the 
mutant status of p53 in the studied cohort (Figure 4B and 
Supplementary Figure 5A).
Concomitant treatment with Auranofin and 
APR-246 selectively kills cancer cells bearing 
mutant p53
Having demonstrated the relevance of NRF2 
modulation by mutant p53 on the viability and migration 
of cancer cells, we next asked if inhibiting the mutant 
p53/NRF2 axis could have a synergistic killing effect on 
cancer cells bearing TP53 GOF mutations. In particular, 
we sought whether inhibiting mutant p53 could impair the 
growth of mutant p53 bearing cancer cells with perturbed 
NRF2 activity. In order to address this question, we 
investigated whether silencing of NRF2 expression would 
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specifically sensitize mutant p53 bearing cells to treatment 
with APR-246, a drug that binds and converts mutant p53 
into a wild type-like, active protein [36]. Indeed, in MDA-
MB-231 and MCF10A+R280K cells silenced for NRF2, 
treatment with APR-246 significantly reduced viability, 
while wt p53 bearing cells (MCF10A or MCF7) silenced 
for NRF2, were not affected by APR-246 (Supplementary 
Figure 5B). These results indicate that targeting of mutant 
p53 with APR-246 synergizes with depleting its partner 
protein NRF2.
We have demonstrated here that the thioredoxin 
system is a downstream target and effector of the mutant 
Figure 5: Concomitant treatment of Auranofin and APR-246 selectively kills cancer cells bearing mutant p53. (A) 
Viability measurements of MDA-MB-231 cells upon TP53, NRF2 or control silencing and 24 hours treatment with APR-246 (25μM), 
Auranofin (2μM) or DMSO. (B) Viability measurements of MDA-MB-231 cells upon TP53, NRF2 or control silencing and 24 hours 
treatment with the indicated compounds (NAC 5mM, Auranofin 2μM, DMSO). (C) Viability measurements of MDA-MB-231 cells upon 
24 hours treatment with upon 24 hours treatment with the indicated compounds (APR-246 25μM, Auranofin 2μM, NAC 5mM, DMSO). 
(D) Western blot analysis of the apoptosis marker PARP p85 in cell lysates of MDA-MB-231 cells treated as in (C). Representative of 2 
biological replicates is shown. Actin levels are reported as loading control; size markers are indicated. (E) CellROX mean fluorescence 
intensity (MFI) of MDA-MB-231 cells treated as in (C). (F) Viability measurements of MCF10A cells overexpressing p53R280K (MCF10A 
+p53R280K), MCF10A cells, and MCF7 cells respectively. Data shown in A-C, E, F are the means ± s.d. of n=3 independent experiments, 
ANOVA test with Bonferroni correction: * p<0.05, ** p<0.01, *** p<0.001.
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p53/NRF2 axis (Figures 2D, 2F, 3 and Supplementary 
Figure 3G). This prompted us to test the efficacy 
of a combined inhibition of mutant p53 and of the 
TXN/TXNRD1 system in killing cancer cells expressing 
mutant p53. Of note, a specific inhibitor of thioredoxin 
reductase, Auranofin, has been already approved for 
clinical use as an antirheumatic agent [37] and clinical 
trials are currently evaluating its effects on various cancer 
types (https://clinicaltrials.gov/ct2/).
We treated MDA-MB-231 cells silenced for mutant 
TP53, NRF2 or control siRNA with 2μM Auranofin. Upon 
treatment, cells showed a significant viability decrease in 
mutant TP53 and in NRF2 silencing conditions (Figure 5A). 
In mutant TP53 and in NRF2 silenced cells the viability 
decrease caused by Auranofin was rescued by adding 
N-acetylcysteine (NAC), a compound which restores the 
antioxidant potential of cells [9] (Figure 5B), indicating 
that the viability decrease is caused by defective ROS 
neutralization. This result suggested that, in cancer cells 
silenced for mutant TP53 or NRF2, Auranofin causes the 
viability decrease by inducing high levels of intracellular 
ROS the cells can not cope with, due to impairment of the 
mechanism activating the required antioxidant systems.
Hence, we next investigated if combining inhibition 
of mutant p53 by APR-246 and inhibition of the 
thioredoxin system by Auranofin could cause a specific 
lethality of mutant p53 bearing cancer cells. As shown 
in Figure 5C the co-treatment led to a significant down-
regulation of MDA-MB-231 cell viability and enhanced 
apoptosis, as indicated by the accumulation of PARP 
p85 fragment (Figure 5D). In these conditions we also 
observed increased protein levels of HO-1 and a decrease 
in Trx protein levels (Figure 5C and Supplementary Figure 
5C). We next assessed the production of ROS in response 
to the drug treatment by CellROX FACS analysis. The 
combination treatment with Auranofin and APR-246 
induced significantly higher accumulation of ROS with 
respect to control cells and to cells treated with either 
APR-246 or Auranofin (Figure 5E), further indicating 
that the increased production of ROS levels beyond a 
manageable threshold could be the reason why combining 
treatments produces synergistic effects in killing cancer 
cells bearing mutant p53. Accordingly, we observed that 
the viability decrease and the apoptosis induction caused 
by the combination treatment were rescued by NAC 
addition (Figure 5C–5E).
A synergistic effect of the Auranofin/APR-246 
treatment was observed also in MCF10A+mtp53R280K, while 
cells bearing wtp53, like MCF10A or MCF7, were not 
significantly affected by the drug combination in the 
investigated concentrations (Figure 5F).
DISCUSSION
In normal cells, the transcription factor NRF2 is a 
key regulator of antioxidant pathways acting as a defense 
mechanism against oxidative stress. However, NRF2 
activity was shown to be essential also for the survival 
of cancer cells by protecting them from the oxidative 
environment that characterizes tumors [1]. Indeed, NRF2 
has been shown to be activated by oncogenic signaling, 
resulting in enhanced cytoprotection of cancer cells [5].
We demonstrate here that missense mutant p53 
is a key interactor of NRF2 and a modulator of its 
transcriptional program, through which it selectively 
promotes a specific pro-survival oxidative stress response 
in cancer cells.
While NRF2-regulated transcripts, including diverse 
components of the oxidative stress response, are all 
activated upon introduction of activated Ras and Myc into 
breast epithelial cells, mutant p53 leads to upregulation 
of thioredoxin (TXN) and proteasome (PSM) systems, 
but to repression of heme oxygenase 1 gene (HMOX1) 
among other NRF2 targets. The difference with other 
oncoproteins known to activate NRF2 is likely due to 
the fact that while Ras or Myc family proteins primarily 
activate NRF2 transcription directly [4, 5], mutant p53 
modulates its activity via protein interaction [14, 38] 
and this binding is required for regulating activation 
and repression of specific NRF2 targets by mutant p53. 
We mapped the region of p53 involved in the binding to 
NRF2 into the initial region of the p53’s DNA-binding 
domain (98-128aa). Of note, this region, which has been 
shown to be structurally affected in multiple mutant p53 
variants, is bound by APR-246 [39], a drug inhibiting 
mutant p53’s gain-of-function and reactivating p53 wild-
type conformation and properties [36]. The localization 
of the mutant p53’s region interacting with NRF2 in this 
domain could explain the observed binding of NRF2 to 
several missense p53 mutant variants and its disruption by 
APR-246 [14].
Our results indicate that mutant p53 binding to 
NRF2 leads to an increased nuclear localization of NRF2 
on ARE-containing regulatory sequences, leading to 
specific effects on NRF2 targets’ transcription, resulting 
in the transcriptional activation of genes such as TXN 
and the proteasome encoding genes, and in the repression 
of others such as HMOX1 and ABCC3 (Figure 6). In 
addition, our experiments suggest that NRF2 targets 
can be divided in two categories. The first category 
consists of NRF2 inducible genes whose expression 
is low in the absence of oxidative stress (ABCC3 and 
HMOX1; Supplementary Figures 2D and 5C). The other 
group consists of basally active NRF2 targets whose 
expression is already high in the same conditions (TXN 
and TXNRD1; Supplementary Figures 2D and 5C). 
Consistently, our ChIP results indicate that the binding 
of NRF2 to the regulatory elements of its basal targets 
is much higher than the binding measured for inducible 
targets. Our results indicate that mutant p53 might 
selectively contribute to repress the inducible NRF2 
targets and cooperate to activate the basal ones.
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The biological effect of the mutant p53/NRF2 
interplay is an increased survival of cancer cells under 
oxidative stress. The presence of increased ROS levels 
is a known feature of tumor microenvironment [40, 41] 
and induction of the thioredoxin/thioredoxin reductase 
(TXN/TXNRD1) system is known to be beneficial for the 
survival of cancer cells [9, 42]. Indeed TXN is a critical 
NRF2 target and belongs to the NRF2 target signature 
activated by mutant p53, whose increased expression 
is associated with poor prognosis in breast cancer. 
Accordingly, high expression of TXN and TXNRD1 has 
been previously associated to high grade breast cancers 
[43]. Consistently, we show here that silencing of TXN 
strongly decreases the survival and migration of breast 
cancer cells under oxidative stress. In contrast, silencing 
of HMOX1 has opposite effects. In agreement, several 
studies suggest that, while having cytoprotective functions 
in untransformed cells, HMOX1 plays a cytotoxic role in 
cancer cells [44, 45].
Overall our results shed new light onto the complex 
role of antioxidant systems in cancer initiation and 
progression. Increased production of ROS is essential to 
enable and sustain a highly metastatic phenotype [46]. 
However by preventing an excess of damage due to ROS 
accumulation, antioxidant systems such as thioredoxin 
or glutathione are also required for cancer initiation, 
and inhibition of these ROS scavenging mechanisms, 
combined with pro-oxidizing agents, seems to be 
effective in the treatment of chemoresistant tumors [9, 40, 
41, 47, 48].
On the basis of our observations, we tested a 
combinations of drugs aimed at blocking the biological 
effects exerted by the mutant p53-NRF2 axis in cancer 
cells. Our results indicate that breast cancer cells 
expressing mutant p53 can be efficiently eliminated 
by combining the two drugs APR-246 and Auranofin. 
The first one is a covalent inhibitor of mutant p53 that 
was also described to affect the cellular redox status by 
targeting selenoprotein thioredoxin reductase 1 [49], 
while Auranofin is a known inhibitor of the thioredoxin 
system [50]. Recently, multiple reports have indicated that 
targeting the thioredoxin system with various drugs could 
be an efficient strategy for killing chemoresistant cancer 
cells [9, 37, 50–52]. Indeed, Auranofin and APR-246 in 
combination turned out to synergistically affect cancer cell 
survival by blocking mutant p53-depentend antioxidant 
systems both directly and indirectly. Interestingly, in 
a recent study mutant p53 was shown to mediate the 
repression of the NRF2 target gene SLC7A11 and a 
concomitant use of APR-246 with a glutathione synthesis 
Figure 6: Model representing mutant p53-mediated tuning of the NRF2-dependent antioxidant pathway. Left, in normal 
conditions, NRF2 is bound by its inhibitor Keap1 and it is directed for proteasomal degradation. Upon activation (e.g. oncogenes, oxidative 
stress), NRF2 translocates into the nucleus where it binds to ARE (antioxidant responsive element) sequences within promoters of target 
genes. Right, mutant p53, when expressed, selectively activates NRF2 downstream targets, thioredoxin and proteasome systems. This 
effects in acquiring the resistance to microenvironmental stress. At the same time mutant p53 by increasing the presence of NRF2 on the 
gene promoters of TXN or TXNRD1 sequesters NRF2 from canonical NRF2 regulatory elements of other NRF2 targets (e.g. HMOX1).
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inhibitor was revealed as an approach to eliminate cancer 
cells with mutant p53 [38]. This result suggests that 
understanding of the mutant p53-depedent tuning of the 
NRF2 program may result in several efficient anti-cancer 
treatment strategies.
Our work revealed the existence of a mutant p53/
NRF2 axis that specifically exploits the thioredoxin 
system to sustain the survival of breast cancer cells 
under oxidative stress. These findings provide important 
advances in the understanding of NRF2 regulation in 
cancer and open up new therapeutic opportunities for 
breast cancers expressing mutant p53.
MATERIALS AND METHODS
Cell lines and treatments
All cell lines were purchased from ATCC. 
Human cell lines MDA-MB-231 (p53 R280K), MDA-
MB-468 (p53 R273H) were cultured in DMEM medium 
(BioWhittaker) supplemented with 10% FCS (ECS0180L, 
Euroclone), and antibiotics (DE17-602E, Lonza). BT-549 
(p53 R249S), H1299 (p53-null) cells were cultured in 
RPMI medium (BioWhittaker) supplemented with 10% 
FBS and antibiotics. SUM-149 (p53 M237I) cells were 
cultured in DMEM:F12 Ham’s medium 1:1, supplemented 
with 10% FCS and antibiotics. MCF7 (p53 wt) were 
cultured in EMEM (BioWhittaker), supplemented with 1% 
non-essential aminoacid solution (Sigma), 10% FBS and 
antibiotics. MCF10A (p53 wt, shTP53 and stable mutant 
p53 overexpressing cell lines) cells were maintained in 
DMEM:F12 Ham’s medium 1:1, supplemented with 5% 
horse serum, insulin (10 μg/ml), hydrocortisone (0.5 
μg/ml) and epidermal growth factor (EGF 20 ng/ml), if 
needed - with addition of selection antibiotics.
All human cell lines were subjected to STR 
genotyping with PowerPlex 18D System and confirmed 
in their identity comparing the results to reference 
cell databases (DMSZ, ATCC, and JCRB databases). 
Mutant p53 cell lines have been confirmed to express 
indicated mutant TP53 variants by sequencing of the 
full-length p53 mRNA [14]. All the cell lines have been 
tested by PCR/IF for the Mycoplasma presence. No cell 
lines used in this study were found in the database of 
commonly misidentified cell lines that is maintained by 
ICLAC and NCBI Biosample. H2O2 (Sigma 216763), 
menadione (Sigma M5625), sodium arsenite (Sigma 
S7400), Auranofin (Enzo Life Sciences BML-2842-
0100) and NAC (N-Acetyl-L-Cysteine, Sigma A7250) 
were resuspended and used as indicated in the respective 
datasheets.
Plasmids
pSR-shRNAp53 PuroR used to stably silence TP53 
expression was a kind gift of R. Agami. si/shRNA resistant 
N-terminally HA-tagged p53 constructs p53R280K and 
p53R175H were generated by first introducing 4 silent 
point mutations in the region targeted by p53 siRNA#1/
shRNA by site-directed mutagenesis in pcDNA-HA-p53, 
subsequent introduction of missense point mutations and 
subcloning of sequenced p53 cds constructs to pMSCV-
HA BlastR retroviral vector.
Transfection
For retrovirus production (stable silencing of TP53 
and ectopic overexpression of mutant p53s) low confluent 
HEK 293GP packaging cells were transfected with 
appropriate vectors by calcium phosphate precipitation. 
After 48-72 hours the virus-containing medium was 
filtered and added to target cells (MDA-MB-231, 
MCF10A or H1299). Cells were selected with puromycin 
(0.5 μg/ml) and/or blasticidin (2 μg/ml).
H1299 cells were transfected using Lipofectamine 
2000 reagent (Invitrogen) following the manufacturer’s 
instructions.
For siRNA transfections, all cells lines were 
transfected at 40-60% confluence with 24 hours interval 
(to increase efficiency of silencing), with 50 nM siRNA 
oligonucleotides using Lipofectamine RNAiMax 
(Invitrogen), following manufacturer’s instructions. After 
48 hours cells were processed. siRNAs coding sequence 
used in this work are listed in the Supplementary Table 1.
Total RNA extraction and RT-qPCR analysis
Total RNA was extracted with QIAzol (Qiagen) 
following manufacturer’s instructions. 1μg of total 
RNA was reverse-transcribed with QuantiTect Reverse 
Transcription (Qiagen). Real-time qPCR in technical 
duplicates from each biological replicate was performed 
using SsoAdvanced™SYBR Green Master Mix (Biorad) 
on a CFX96 Real-Time PCR System (Biorad). Expression 
levels are given relative to ACTB, GAPDH or histone 
H3. The list of qPCR primers used is provided in the 
Supplementary Table 2. Key NRF2 downstream targets 
analyzed in Figure 1A were selected from available 
datasets. For the following experiments we narrowed 
down the signatures to the most strongly regulated genes 
by mutant p53.
ChIP
Chromatin was immunoprecipitated with p53 
DO-1 (Santa Cruz) or NRF2 antibody (Abcam), as 
previously described [14]. As negative controls IgGs 
purified from rabbit or mouse serum were used. 
Coimmunoprecipitated DNA was analyzed by real-time 
PCR on a CFX96 Real-Time PCR System (Biorad), 
using SsoAdvanced™SYBR Green Master Mix (Biorad). 
Promoter occupancy was calculated as percent of input 
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chromatin immunoprecipitated using the 2-DCt method. 
Primer sequences are shown in the Supplementary Table 3.
Statistics and reproducibility
The statistical analysis of experimental results 
is described in the figure legends, along with number 
of biological replicates and plotted error types (s.d. – 
standard deviation). Statistic tests were performed and p-
value thresholds were obtained using GraphPad 6.0.
Patient survival and mutation status association 
analysis
To verify the correlation of the gene signatures 
and breast cancer clinical data, survival analysis was 
performed on a breast cancer meta-dataset composed by 
3458 samples using the Km-plotter online analysis tool 
[53]. In order to perform the analysis on the greatest 
possible number of patients, for each gene, we selected 
only HGU133A probe-sets. The samples were split 
into two groups according to median expressions of the 
proposed signatures. The two groups were then compared 
by survival analysis. The Kaplan-Maier curves of relapse 
free survival time (RFS), the hazard ratio with 95% 
confidence intervals and log-rank test p-values were 
calculated. For each signature we selected the top 3 or 4 
genes up-regulated or down-regulated by mutant p53.
Gene expression data, TP53 mutation status and 
clinical annotation for Breast Invasive Carcinoma, (TCGA 
datasets) have been obtained from Cancer Genomics 
Data Server using the cgdsr package for R (https://cran.r-
project.org/web/packages/cgdsr/index.html). The datasets 
were chosen for analysis according to the wt TP53 vs 
mutant TP53 status availability, with TP53-null samples 
excluded. For each patient we defined the levels of 
mtp53 upregulated or mtp53 not upregulated signatures 
expression as the mean of the expression values of all the 
genes included in the signature. The genes composing 
each used signature are described in Figure 4A, 4B. 
The statistical differences between the distributions 
of expression values in the two molecular conditions 
(mutated TP53 and wt TP53) were calculated by Mann–
Whitney U test in R/Bioconductor environment (R Core 
Team, 2013).
Pearson’s Chi-squared test with Yates’ continuity 
correction has been performed to test independence 
between TP53 status and a signature expression. All 
statistical analysis has been performed using R statistical 
analysis environment.
Western blot analysis
Total cell extracts were prepared in RIPA buffer 
without SDS (150mM NaCl, 50mM Tris-HCl pH8, 1mM 
EDTA, 1% NP-40, 0.5% Na-deoxycholate) supplemented 
with 1 mM PMSF, 5 mM NaF, 1 mM Na3VO4, 10μg/
ml CLAP protease inhibitor cocktail (Sigma). Protein 
concentration was determined with Bio-Rad Protein Assay 
Reagent (Bio-Rad). Lysates were resolved by SDS/PAGE 
and transferred to nitrocellulose (Millipore). Western blot 
analysis was performed according to standard procedures 
using primary antibodies listed in Supplementary Table 4. 
Western blots experiments were performed in at least 2 
biological replicates, the representative is shown.
Cell fractionation
Cells were scraped in PBS and washed two times. 
The pellet obtained after the last centrifugation was 
resuspended in Cytoplasmic-buffer (10mM HEPES 
pH7.9, 1.5mM MgCl2, 10mM KCl, 0.5mM DTT, 0.1% 
NP-40) supplemented with inhibitors (1mM PMSF, 5mM 
NaF, 10μg/ml CLAP, 1mM Na3VO4); lysis was obtained 
gently pipetting a couple of times. After 3’ in ice, lysates 
were centrifuged at 2500g for 5’ at 4°C; the supernatant 
was collected as the cytoplasmic fraction. The pellet was 
washed twice in Wash-buffer (10mM HEPES pH7.9, 
1.5mM MgCl2, 10mM KCl, 0.5mM DTT) and then Nuclei 
in the pellet were resuspended in Nuclear-buffer (20mM 
HEPES pH7.9, 1.5mM MgCl2, 420mM NaCl, 0.2mM 
EGTA, 0.5mM DTT, 25% glycerol) supplemented with 
inhibitors (1mM PMSF, 5mM NaF, 10μg/ml CLAP, 1mM 
Na3VO4); nuclear extract was recovered by centrifugation 
at 15000g for 15’ at 4°C.
Protein interaction studies
Coimmunoprecipitation experiments with endogenous 
proteins were performed by lysing cells in the Co-IP buffer 
(NaCl 150mM, Tris-HCl pH8 50mM, EDTA 1mM, NP40 
0.5%, glycerol 10%) with protease inhibitors. Samples were 
cleared by centrifugation for 30 min at 13000g at 4°C and 
incubated overnight at 4°C with the specific antibody. After 
1h incubation with protein G-Sepharose (GE Healthcare), 
immunoprecipitates were washed three times in Co-IP 
buffer, resuspended in a sample buffer, and analyzed by 
western blotting. For Co-IP of endogenous p53 or NRF2, 
DO-1 (sc-126, Santa Cruz) and EP1808Y (ab62352, Abcam) 
primary antibodies were used respectively, and mouse or 
rabbit normal IgGs (Santa Cruz) as negative controls.
Immunofluorescence
Cells were fixed in 4% paraformaldehyde for 20 
min, washed with PBS, permeabilized with Tryton 0.1% 
for 5 min and blocked in PBS + FBS 3% for 30 min. 
Antigen recognition was done by incubating primary 
antibodies against p53 and NRF2 for 1hr at 37°C, followed 
by incubation with AlexaFluor 568 and 488 conjugated 
secondary antibodies. Nuclei were counterstained with 
Hoechst 33342 (LifeTechnologies). Representative 
fluorescence images of 3 biological replicates were 
taken with a x 630 magnification on a Leica DM4000B 
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microscope equipped with a Leica DFC420C camera and 
acquired with Leica Application Suite 2.5.0 R1 (Leica 
Microsystems).
Migration assay
Migration assay were performed by seeding cells at 
a density of 5,000 cells per well in 24-well PET inserts 
(8.0 mm pore size, Falcon). After 16 hr, cells that passed 
through the filter were fixed in 4% PFA, stained with 
0.5% crystal violet and counted with a x 20 objective on 
CK30 Olympus optical microscope. Results shown are the 
average of 6 fields of view of 6 separate filters for each 
experimental condition.
ROS detection
For CellROX analysis, CellROX® Green Reagent 
(Thermo Fisher Scientific) was used as previously described 
[54]. Analyses were performed on a FACSCalibur cell 
sorter (Becton Dickinson) and data were analyzed with 
FlowJo software for Mac (FlowJo, LLC 2013-2016).
Viability assay
6-10x104 cells were plated in 96-well plates (white, 
transparent bottom), after 24 hours they were treated 
as indicated in figures and assayed for viability using 
ATPlite™ OneStep reagent (Perkin Elmer), according to 
the manufacturer’s instructions. Luminescence intensity 
was measured using EnSpire plate fluorometer (Perkin 
Elmer). 3 biological replicates were performed, for each 
experiments means from 3 technical replicates (3 wells) 
were used.
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